FindTrial
Sign In

Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia

A Double-blind, Randomized, Placebo-controlled Trial With Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00999505
Enrollment
40
Registered
2009-10-21
Start date
2010-05-31
Completion date
2011-09-30
Last updated
2011-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

Schizophrenia, Amantadine, Residual symptoms

Brief summary

Amantadine as add-on therapy to antipsychotics may improve schizophrenia positive, negative and cognitive symptoms.

Interventions

DRUGAmantadine

Amantadine 200mg twice a day over 12 weeks

DRUGPlacebo

Placebo capsules twice a day over 12 weeks

Sponsors

Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Under antipsychotics with residual symptoms

Exclusion criteria

* Pregnancy * Lactation

Design outcomes

Primary

MeasureTime frame
Scores in Brief Psychiatric Rating ScaleBaseline, 4 weeks, 8 weeks, 12 weeks

Countries

Brazil

Contacts

Primary ContactClarissa S Gama, MD, PhD
csgama@yahoo.com55-51-33598745

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026